INVA Stock Analysis: Buy, Sell, or Hold?
INVA - Innoviva, Inc. Common Stock
$21.25
0.29 (1.38%)
â˛
5d:
+2.41%
30d:
-0.14%
90d:
-2.52%
WAIT
LOW Confidence
Analysis Updated: Aug 18, 2026 12:00 AM ET
Earnings: Aug 05, 2026
0d
Get Alerted When INVA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: INVA is fairly priced but lacks strong directional signals. At -2.3% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: INVA is fairly priced but lacks strong directional signals. At -2.3% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$36.28
Based on 9.9% avg growth
INTRINSIC VALUE TODAY
$22.53
5.7% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: INVA is currently trading at $21.25, which is considered fair relative to its 30-day fair value range of $20.79 to $21.79. The stock's valuation (Forward PE: 9.6) is in line with its historical norms (10.3). Remarkably, the market is currently pricing in an annual earnings decline of 2.3% over the next few years. This pessimistic expectation contrasts with the company's recent 590.4% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, INVA is in a strong downtrend. Immediate support is located at $20.20, while resistance sits at $22.09.
Market Sentiment: INVA scores 71/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $35.00 (+64.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, INVA is in a strong downtrend. Immediate support is located at $20.20, while resistance sits at $22.09.
Market Sentiment: INVA scores 71/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $35.00 (+64.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$20.79 -
$21.79
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
86.5%
Protect Your Profits
Holding INVA? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (71/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 64.7% below Wall St target ($35.00)
- WARNING: Composite score 51/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$20.79 -
$21.79
Current vs Trading Range
FAIR
Expected Move (7 Days)
Âą$0.95
(4.4%)
Support & Resistance Levels
Support Level
$20.20
Resistance Level
$22.09
Current Trend
Strong Downtrend
Technical data as of
Aug 18, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.62
Wall Street Target
$35.00
(+64.7%)
Revenue Growth (YoY)
19.3%
Earnings Growth (YoY)
590.4%
Profit Margin
81.2%
Valuation Discount vs History
-2.3% cheaper
PE vs Historical
9.6 vs 10.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-2.3%
(market-implied from PE analysis)
1-Year Target
$20.76
(-2%)
2-Year Target
$20.28
(-5%)
3-Year Target
$19.82
(-7%)
3-Yr Target (if PE normalizes)
(PE: 10â10)
$21.23
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.1, Growth: 15.7%)
$68.85
(+224%)
Base:
(SPY PE: 9.6, Growth: 15.7%)
$32.92
(+55%)
Bear:
(PE: 8.2, Growth: 15.7%)
$27.98
(+32%)
đ
Valuation based on Current Earnings
Trailing PE: 4.92 | Current EPS (TTM): $4.26
Bull Case
$11.96
(-44%)
Analyst growth -48.1%, PE expands to 5.4
Base Case
$10.87
(-49%)
Market implied -48.1%, PE stable at 4.9
Bear Case
$14.25
(-33%)
Severe decline -20.0%, PE contracts to 4.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 9.6 to 10.3
Stabilization Target:
$22.76
(+7.1%)
PE Expansion Potential:
+7.1%
Share & Embed Analysis
Last updated: August 18, 2026 7:43 PM ET
Data refreshes hourly during market hours. Next update: 8:43 PM
Data refreshes hourly during market hours. Next update: 8:43 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INVA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$49 | 52 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 31 SELL |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1100 | 40 SELL |
|
MLTX
MoonLake ImmunotherapeutâĻ |
STRONG BUY
16 analysts |
$29 | 60 BUY |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$121 | 51 HOLD |
Advanced INVA Option Strategies
Professional options setups generated by AI based on today's INVA price and gamma walls.
